Researchers Submit Patent Application, "Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid Tumors", for Approval (USPTO 20240390360).

Researchers have submitted a patent application for a therapeutic combination of orally administered paclitaxel, a P-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors. The application aims to address the need for more effective therapies for relapsed/refractory lung cancer patients, as current FDA-approved therapies do not provide a response rate greater than 20%. The combination of oral paclitaxel, Encequidar, and pembrolizumab may enhance immune activation and tumor cell death, offering potential benefits for treating solid tumors. [Extracted from the article]